|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C12N 15/113 | |
| C12N 15/88 | |||
| A61K 31/712 | |||
| A61K 31/713 | |||
| A61K 9/127 | |||
| A61P 35/00 |
| (11) | Patento numeris | 2279254 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 09731866.1 |
| Europos patento paraiškos padavimo data | 2009-04-15 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-02-02 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-07-05 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/CA2009/000496 |
| Data | 2009-04-15 |
| (87) | Numeris | WO 2009/127060 |
| Data | 2009-10-22 |
| (30) | Numeris | Data | Šalis |
| 45228 P | 2008-04-15 | US |
| (72) |
MACLACHLAN, Ian, CA
YAWORSKI, Edward, CA
LAM, Kieu, CA
JEFFS, Lloyd B., CA
PALMER, Lorne R., CA
|
| (73) |
Protiva Biotherapeutics Inc.,
100-8900 Glenlyon Parkway, Burnaby, British Columbia V5J 5J8,
CA
|
| (54) | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY |
| NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY |